Y Intercept Hong Kong Ltd Has $1.08 Million Stock Holdings in LivaNova PLC $LIVN

Y Intercept Hong Kong Ltd lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 11.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,038 shares of the company’s stock after selling 3,025 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in LivaNova were worth $1,082,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its stake in shares of LivaNova by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 179,546 shares of the company’s stock worth $7,053,000 after purchasing an additional 3,668 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of LivaNova by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company’s stock worth $1,840,000 after purchasing an additional 2,901 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of LivaNova by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company’s stock worth $817,000 after purchasing an additional 500 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of LivaNova by 28.6% during the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock worth $1,897,000 after purchasing an additional 10,733 shares during the last quarter. Finally, CWM LLC increased its stake in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of LivaNova stock opened at $52.58 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The firm has a fifty day moving average price of $54.42 and a two-hundred day moving average price of $47.98. The company has a market cap of $2.87 billion, a PE ratio of -13.52 and a beta of 0.95.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same period in the prior year, the firm earned $0.93 EPS. The business’s revenue was up 10.6% on a year-over-year basis. Analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on LIVN shares. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the stock a “neutral” rating in a research note on Wednesday, October 1st. Barclays increased their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research note on Wednesday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.